Armata Pharmaceuticals - Stock Price History | ARMP

Historical daily share price chart and data for Armata Pharmaceuticals since 2021 adjusted for splits. The latest closing stock price for Armata Pharmaceuticals as of October 20, 2021 is 3.36.
  • The all-time high Armata Pharmaceuticals stock closing price was 1155.48 on October 12, 2015.
  • The Armata Pharmaceuticals 52-week high stock price is 10.48, which is 211.9% above the current share price.
  • The Armata Pharmaceuticals 52-week low stock price is 2.56, which is 23.8% below the current share price.
  • The average Armata Pharmaceuticals stock price for the last 52 weeks is 4.03.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Armata Pharmaceuticals Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 3.4002 3.2452 4.8500 2.5800 2.9849 -8.16%
2019 3.8991 3.2941 5.5882 2.7500 3.2500 12.48%
2018 13.3501 14.1457 26.1905 2.5504 2.8894 -79.57%
2017 29.8025 67.9412 75.6303 9.9874 14.1457 -77.05%
2016 301.4709 574.2297 735.2941 61.6246 61.6246 -88.94%
2015 811.4800 1088.2353 1155.4762 420.1681 557.4230 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.082B $0.001B
Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company's principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.972B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $11.985B 20.30
Biohaven Pharmaceutical Holding (BHVN) United States $8.378B 0.00
Emergent Biosolutions (EBS) United States $2.740B 6.61
Arcus Biosciences (RCUS) United States $2.509B 0.00
Myovant Sciences (MYOV) United Kingdom $1.869B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.763B 0.00
Zymeworks (ZYME) Canada $1.061B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.333B 0.00
Enzo Biochem (ENZ) United States $0.157B 15.43